Systematic Internalizers: An Ambitious Regulation Caught in the Crossfire

The SI regime has proven to be the most fragile piece of regulation, as its legal loopholes have triggered a series of political events and has been established as the market’s most notorious law.

crown-waters0517

There have been dark clouds gathering over the European Parliament lately and some members fear that the systematic internalizers (SI) regime might end up being Mifid II’s Achilles’ heel. The SI regime is suffering increased notoriety due to its unique complexity and a series of events that triggered public disputes between regulators, politicians and market participants. 

The Delay

It all started with a delay. The SI regime is the only piece of Mifid II to receive an extension and is

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Waterstechnology? View our subscription options

Register for free

Access two articles, our IMD and Waters Wraps, plus a member newsletter. Find out more.

All fields are mandatory unless otherwise highlighted.

This address will be used to create your account

Removal of Chevron spells t-r-o-u-b-l-e for the C-A-T

Citadel Securities and the American Securities Association are suing the SEC to limit the Consolidated Audit Trail, and their case may be aided by the removal of a key piece of the agency’s legislative power earlier this year.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here